Compare DexCom, Inc. (DXCM) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Illinois Tool Works Inc. — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Illinois Tool Works Inc. trades at $264.18 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is far larger — about 2.3× DexCom, Inc.'s market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Illinois Tool Works Inc. for 67 Days on average.
| DXCM | ITW | |
|---|---|---|
Market Cap | $31.86B | $74.38B |
Volume | 3,607,070 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $92.34 | $299.60 |
52-Week Low | $54.84 | $241.07 |
Typical Hold Time | 62 Days | 67 Days |
Enterprise Value | $31.32B | $83.23B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
ITW trades at $261.15, down 2.24% on the day, with a bearish technical signal from moving averages. The company demonstrates strong profitability with a 19.39% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its status as a Dividend King, having raised its dividend to $1.72 per share, with a forward yield of approximately 2.57%.
The outlook is mixed; strong fundamentals and a consensus price target of $280.14 suggest upside potential, but a high P/E ratio of 23.65 and bearish technical indicators indicate near-term pressure. Key risks include economic sensitivity and rising debt levels, while institutional buying provides some support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
